NKGen Biotech, Inc. NKGN
0.01
0.00
0.00%
as of 24 Sep
- Market cap
- $8.8M
- P/E
- 0.0×
Follow NKGN
Growth Flags
show if company had growth for consecutive years
| Dec '17 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | — | — |
P/S ratio |
— | — | 0.00 | — | — |
P/FCF ratio |
— | — | 0.00 | — | — |
P/Operating CF |
— | — | (11.57) | — | — |
P/B ratio |
— | — | 40.46 | — | — |
Price to Tangible BV |
— | — | 40.46 | — | — |
EV/Sales |
— | — | 0.00 | — | — |
EV/EBITDA |
— | — | 0.00 | — | — |
EV/Operating CF |
— | — | (3.32) | — | — |
EV/FCF |
— | — | (3.32) | — | — |
Quick Ratio |
— | 0.91 | 0.01 | 0.01 | 0.00 |
Current Ratio |
— | 1.34 | 0.02 | 0.05 | 0.04 |
Net Debt/EBITDA |
— | 0.69 | (0.50) | (0.34) | (1.69) |
Debt/Assets |
0.00% | 0.00% | 71.37% | 60.25% | 267.97% |
Debt/Equity |
— | 0.00 | 7.46 | (0.17) | (0.62) |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 1.54 | 0.84 | 0.26 | 0.47 |
Capex/Depreciation |
— | — | (0.13) | (0.04) | (0.01) |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 |
| — | 0.00% | 573.40% | 290.40% | 68.87% | |
| — | (1.14%) | (28.09%) | (505.65%) | (270.76%) | |
ROIC |
— | 0.00% | (116.15%) | 0.00% | 0.00% |
Return on Tangible Assets |
— | (154.28%) | (2,367.61%) | 359.68% | 104.91% |
Average Days of Receivables |
— | — | 137.47 | — | — |
Research and Development Expense of Revenue |
— | — | 21,748.05% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 9,946.75% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 89.61% | 0.00% | 0.00% |
Graham Net Nets |
— | — | (0.23) | — | — |
Graham Number |
— | — | 0.00 | — | — |
Earnings Yield |
— | — | (42.28%) | — | — |
Free Cash Flow Yield |
— | — | (35.67%) | — | — |
Revenue per Share |
— | 0.00 | 0.01 | 0.00 | 0.00 |
Operating CF per Share |
— | (0.10) | (3.55) | (1.42) | (0.72) |
Capex per Share |
— | 0.00 | (0.03) | 0.00 | 0.00 |
Free Cash Flow per Share |
— | (0.10) | (3.57) | (1.43) | (0.72) |
Cash per Share |
— | 0.11 | 0.02 | 0.02 | 0.01 |
Shareholders Equity per Share |
— | (0.72) | 0.25 | (3.80) | (2.42) |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | (0.72) | 0.25 | (3.80) | (2.42) |
Free Cash Flow |
— | (1.52) | (22.72) | (22.00) | (20.89) |
Working Capital |
— | 0.64 | (14.39) | (37.52) | (55.51) |
Capital Expenditures |
— | — | (0.16) | (0.05) | (0.01) |
Net Current Asset Value |
— | (182.55) | (14.42) | (73.24) | (83.68) |
EV/EBIT |
— | — | 0.00 | — | — |
Capex to Sales |
— | — | 2.12 | 0.00 | 0.00 |
Net Profit Margin |
— | 0.00% | (34,745.45%) | 0.00% | 0.00% |
Price to Operating Income |
— | — | 0.00 | — | — |
| Other line items | |||||
Depreciation/Fixed assets |
— | — | 0.08 | 0.08 | 0.10 |
Cash ROIC |
— | 16.61% | (285.55%) | 75.09% | 130.56% |
Accounts Receivable Turnover |
— | — | 0.00 | — | — |
Accounts Payable Turnover |
— | — | 0.01 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | — | — |
Average Days of Payables |
— | 0.00 | 53,776.67 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | — | — |
Average Payables |
— | — | 1.35 | 8.02 | 14.53 |
Average Assets |
— | 87.10 | 95.26 | 16.41 | 16.36 |
Average Common Equity |
— | — | (4.67) | (28.56) | (64.30) |
Columns are period end dates